Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

about

Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study.Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

P2860

Q55005726-36E01A9E-3DAA-47F8-8B41-CF2E2791B0C5 Q56362782-43526FA4-A790-4964-95B6-B5970A234178

P2860

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

Item

http://www.wikidata.org/entity/Q47236245

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Carfilzomib-Associated Cardiov ...... atic Review and Meta-analysis.

@en

Carfilzomib-Associated Cardiov ...... atic Review and Meta-analysis.

@nl

type

Item

label

Carfilzomib-Associated Cardiov ...... atic Review and Meta-analysis.

@en

Carfilzomib-Associated Cardiov ...... atic Review and Meta-analysis.

@nl

prefLabel

Carfilzomib-Associated Cardiov ...... atic Review and Meta-analysis.

@en

Carfilzomib-Associated Cardiov ...... atic Review and Meta-analysis.

@nl

P1476

Carfilzomib-Associated Cardiov ...... atic Review and Meta-analysis.

@en

P2093

Adam J Waxman

http://www.w3.org/2001/XMLSchema#string

Bonnie Ky

http://www.w3.org/2001/XMLSchema#string

Brendan M Weiss

http://www.w3.org/2001/XMLSchema#string

Dan T Vogl

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Joseph Carver

http://www.w3.org/2001/XMLSchema#string

Rupal O'Quinn

http://www.w3.org/2001/XMLSchema#string

Suparna Clasen

http://www.w3.org/2001/XMLSchema#string

Wei-Ting Hwang

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis

Meta-analysis in clinical trials

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

Metaprop: a Stata command to perform meta-analysis of binomial data

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

P304

e174519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1001/JAMAONCOL.2017.4519

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Adam D Cohen

Alfred L Garfall

P577

2017-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29285538

http://www.w3.org/2001/XMLSchema#string

P932

5885859

http://www.w3.org/2001/XMLSchema#string

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

about

P2860

P2860

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932